Repurposing Recursion

With a $60 million series B round and a fourth pharma partnership, Recursion Pharmaceuticals Inc. plans to expand the use of its phenotypic screening platform to a broader range of chemical libraries and therapeutic areas.

Recursion’s platform applies advanced imaging, artificial intelligence and machine learning tools to low-tech cellular disease models to create morphological signatures of disease and rapidly screen for compounds that can reverse them (see BioCentury Innovations, April 20). ...